CTOs on the Move


 
Allpro Inc is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

behavior therapy clinic

behavior therapy clinic is a Encino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nova Health Systems Inc

Nova Health Systems Inc is a Utica, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenter

Xenter, Inc. is a privately held company headquartered in Salt Lake City, Utah, that is focused on developing new wireless medical device technologies, innovative digital health tools that will enable individual patients to own and manage their health information, and novel therapeutic drugs utilizing Physical Intelligenceā„¢ and patient-supplied data. Xenter has assembled a team of medical scientists, chemical engineers, medical device engineers, researchers, data scientists, and some of the world`s most accomplished entrepreneurs and industry veterans to solve some of the largest challenges in healthcare, medicine and engineering.

Advanced Medical Electronics Corporation

Advanced Medical Electronics Corporation is a Maple Grove, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.